USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Vital Signs - From Pill to Patch: Will Oral Administration of Neurological Drugs Change in the Future?
Vital Signs - From Pill to Patch: Will Oral Administration of Neurological Drugs Change in the Future?
RELEASE DATE
09-May-2011
09-May-2011
REGION
North America
North America
Research Code: 9561-00-C5-00-00
SKU: HC00624-NA-MR_04097
$1,500.00
Special Price $1,125.00 save 25 %
In stock
SKU
HC00624-NA-MR_04097
Description
This issue of Vital Signs, released on May 9, 2011, provides a strategic insight on the future of neurological drugs market.
Additionally, a company spotlight is provided for AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Reimbursement and regulatory news from the FDA is also provided for week of April 18, 2011.
Table of Contents
This week's issue
Popular Topics
This issue of Vital Signs, released on May 9, 2011, provides a strategic insight on the future of neurological drugs market. Additionally, a company spotlight is provided for AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Reimbursement and regulatory news from the FDA is also provided for week of April 18, 2011.
| No Index | Yes |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | 9561-00-C5-00-00 |
| Is Prebook | No |